Administration of Soliris may result in infusion reactions, including anaphylaxis or other hypersensitivity reactions. In patients with PNH, the most frequently reported adverse events observed with ...
- 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks - “We are pleased that the Japanese health ...
LAUSANNE, Switzerland--(BUSINESS WIRE)--Alexion announced today that the European Commission (EC) has approved updates to the EU label for the therapeutic indication of Soliris ® (eculizumab) in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results